Adalimumab monotherapy and combination with methotrexate showed similar drug survival and PASI75 response rates in plaque psoriasis patients. Methotrexate reduced antidrug antibody levels but did not ...

Adalimumab and ixekizumab show comparable effectiveness in improving joint outcomes and achieving remission in patients with psoriatic arthritis over 12 months, according to a real-world study.

An article published in the Journal of the European Academy of Dermatology and Venereology investigated the long-term effectiveness and safety of adalimumab in combination with methotrexate versus ...

In people with psoriasis taking adalimumab, there was no significant difference between adalimumab monotherapy and adalimumab with concomitant methotrexate, according to a recent report in JAMA ...

Prescriptions for an adalimumab biosimilar among new users rose from 0% to 24% after CVS Caremark added it to its formulary, ...

(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...